Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences to $105 from $95 and keeps a Buy rating on the shares ahead of the Q1 report. The analyst cites stable competitive trends for the target increase, with no evidence of a share shift reversal back to late 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- SMART data a ‘modest win’ for Medtronic, says Jefferies
- Edwards Lifesciences price target raised to $98 from $90 at Citi
- Edwards Lifesciences Announces Upcoming Board Chair Transition
- Edwards Lifesciences upgraded to Positive from Mixed view at OTR Global
- Edwards Lifesciences price target raised to $103 from $95 at Morgan Stanley
